Wang, Weimin
Chang, Xiangyun
Lehrskov, Lars Lang
Li, Ling
Nordentoft, Mads
Quan, Jinxing
Sha, Yubo
Zhong, Xing
Yang, Caixian
Zhu, Dalong http://orcid.org/0000-0002-1064-1261
Funding for this research was provided by:
Novo Nordisk
Article History
Received: 10 October 2023
Accepted: 16 January 2024
First Online: 5 March 2024
Declarations
:
: Weimin Wang, Xiangyun Chang, Ling Li, Jinxing Quan, Yubo Sha, Caixian Yang, and Dalong Zhu declare that they have no competing interests. Mads Nordentoft is an employee of, and also holds shares in, Novo Nordisk A/S. Lars Lang Lehrskov was an employee of and held shares in Novo Nordisk A/S at the time of the study completion. Lars no longer works for Novo Nordisk; current affiliation is Kirurg hos Kirurgisk Klinik, Allerød, Denmark. Xing Zhong is an employee of, and also holds shares in, Novo Nordisk (Shanghai) Pharma Trading Co, Ltd.
: The study was conducted in accordance with the Declaration of Helsinki [CitationRef removed] and the Guidelines for Good Pharmacoepidemiology Practices [CitationRef removed]. Informed consent was obtained from each participant, granting permission to obtain and process the medical record data needed to complete the study. Prior to study initiation, the protocol, any amendments, patient information/informed consent form (ICF), any other written information to be provided to the patient, and patient enrolment procedures were reviewed and approved by an independent ethics committee (IEC)/institutional review board (IRB) (or other appropriate bodies as required locally). A list of the IECs/IRBs that reviewed and approved the protocol, including approval dates, is provided in the Supplementary Appendix.